Bioage Labs Inc (BIOA) Stock Price, Quote & News

Company Profile

BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 510 806 1445

Website: bioagelabs.com

Address:

1445A South 50th Street, Richmond, United States

Iightning Dec. 4 at 7:55 AM

1ightning® Premium Options Alert (Actionable) Ticker: $BIOA Contract: Dec 19 $2.5C Entry: 6.50 Exit: 10.38 Return: +59.69% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 2 at 2:24 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $BIOA **Contract:** Dec 19 $10C **Entry:** 0.62 **Exit:** 0.86 **Return:** **+37.70% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Iightning Nov. 26 at 5:21 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.50 Exit: $0.71 | Profit: 41.95% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:28 PM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.50 Exit: $0.71 | Profit: 41.95% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:23 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.50 Exit: $0.71 | Profit: 41.95% ROI | https://1ightning.com

0 · Reply

VERY_ Nov. 23 at 12:38 PM

$BIOA $AUTL $RCKT $SPY lol wtf

0 · Reply

Iightning Nov. 22 at 1:34 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:56 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:40 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 10:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 7, 2025, 9:00 AM EST - 26 days ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Nov 5, 2025, 7:45 AM EST - 4 weeks ago

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy

Oct 29, 2025, 6:15 AM EDT - 5 weeks ago

Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?

Oct 26, 2025, 6:33 PM EDT - 5 weeks ago

BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?

Sep 15, 2025, 9:30 AM EDT - 2 months ago

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Aug 20, 2025, 4:30 PM EDT - 3 months ago

BioAge Labs to Present at Upcoming Investor Conferences

Aug 15, 2025, 9:00 AM EDT - 3 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Aug 6, 2025, 11:14 PM EDT - 4 months ago

BioAge Labs (BIOA) Q2 Revenue Hits $2.4M

Aug 6, 2025, 4:30 PM EDT - 4 months ago

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jun 21, 2025, 6:00 PM EDT - 5 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Jun 17, 2025, 9:00 AM EDT - 6 months ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

May 6, 2025, 4:30 PM EDT - 7 months ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 20, 2025, 4:30 PM EDT - 9 months ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Mar 10, 2025, 9:30 PM EDT - 9 months ago

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

Mar 10, 2025, 6:33 PM EDT - 9 months ago

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 7, 2025, 4:11 PM EST - 9 months ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

Mar 6, 2025, 1:30 PM EST - 9 months ago

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO - Hagens Berman

Mar 5, 2025, 3:45 PM EST - 9 months ago

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 3, 2025, 3:19 PM EST - 9 months ago

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman

Mar 2, 2025, 7:23 AM EST - 9 months ago

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

Mar 1, 2025, 6:00 PM EST - 9 months ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman

Feb 28, 2025, 3:30 PM EST - 9 months ago

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Feb 27, 2025, 9:24 AM EST - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 27, 2025, 5:45 AM EST - 9 months ago

Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

Feb 23, 2025, 9:24 AM EST - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 21, 2025, 3:17 PM EST - 10 months ago

BIOA SECURITIES NEWS: BioAge has been Sued for Securities Violations - Investors are Alerted to Contact BFA Law by March 10 Legal Deadline

Feb 20, 2025, 4:30 PM EST - 10 months ago

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

Iightning Dec. 4 at 7:55 AM

1ightning® Premium Options Alert (Actionable) Ticker: $BIOA Contract: Dec 19 $2.5C Entry: 6.50 Exit: 10.38 Return: +59.69% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 2 at 2:24 AM

0 · Reply

Iightning Nov. 26 at 5:21 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.50 Exit: $0.71 | Profit: 41.95% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:28 PM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.50 Exit: $0.71 | Profit: 41.95% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:23 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.50 Exit: $0.71 | Profit: 41.95% ROI | https://1ightning.com

0 · Reply

VERY_ Nov. 23 at 12:38 PM

$BIOA $AUTL $RCKT $SPY lol wtf

0 · Reply

Iightning Nov. 22 at 1:34 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:56 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:40 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 10:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $BIOA Dec 19 $10 Call | Enter: $0.49 Exit: $0.92 | Profit: 88.80% ROI | https://1ightning.com

0 · Reply

TalkMarkets Nov. 18 at 2:21 PM

Top 3 #Biotech #Stocks Capitalizing On The #AI Revolution $BIOA $NMRA $RLAY https://talkmarkets.com/content/stocks--equities/top-3-biotech-stocks-capitalizing-on-the-ai-revolution?post=538291

0 · Reply

stockwitsuser2449 Nov. 7 at 12:29 PM

$QURE $BIOA $DYN and $NPCE now. glta

0 · Reply

stockwitsuser2449 Nov. 3 at 6:14 PM

$QURE just need my $BIOA and $DYN puts to pay this big

0 · Reply

stockwitsuser2449 Oct. 28 at 6:06 PM

$LUNG whats a better short this or $BIOA ...don't hate just wondering opinions of shorts (also $DYN why not ...)

1 · Reply

stockwitsuser2449 Oct. 28 at 2:04 PM

$BIOA under 6 please :)

0 · Reply

Lunaris_2721 Oct. 27 at 3:10 PM

$BIOA

0 · Reply

agamemnus Oct. 26 at 3:16 PM

$VTYX $BIOA One of these biotechs had amazing Phase 2 data. The other one has a drug in the same class without Phase 2 data.

1 · Reply

vmst1 Oct. 26 at 2:49 AM

$BIOA With Ventyx positive results of it cardiometabolic drug in phase 2, BIOA had a "NLRP3 inhibitor success" rally for about 30%. Most missed the fact that Ventyx was also measuring weigh loss benefit, which was not observed in this phase 2 study but the company was enthusiastic about due to its preclinical results yielding weigh loss and lean mass relative maintenance. BIOA has the same opinion and its preclinical results purportedly for BGE 102 data showed powerful weight reduction both as monotherapy and in combo with GLP1. Ventyx CEO in the conference after the results did state that this study puts to rest the theory that NLRP3 pathway can reduce the weight. But VTYX was also measuring inflammation reduction so at least that link was proven. Problem with BIOA is that it classifies its study as Obesity drug. In fact with Ventyx its price should have gone down a bit as BGE 102 is the most advanced drug in the pipeline. Unless they have a differentiated drug in some specific way.

1 · Reply

josh77 Oct. 25 at 7:45 PM

$ICU Combined Recovery Path If SeaStar achieves positive adult trial data, strategic partnerships, and growing pediatric revenue, the stock could realistically return to the $5–$10 range over the next 12–18 months. $HKPD $BIOA $MRNO $TTRX

1 · Reply

xrpmoonbaby Oct. 24 at 2:01 PM

$BIOA will probably head to mid to low 6s and consilidate yhere

0 · Reply

Maximum_Gains Oct. 24 at 2:54 AM

Make sure to keep eyes on ticker AWX for tomorrow.💎 Last time AWX woke up this ran over $5+. With how crazy current market is, AWX can potentially see double digit. Don't miss this opportunity bulls. $SONN $SONM $MNRS $BIOA .

0 · Reply

StockScanners Oct. 24 at 12:51 AM

$BIOA reached 8.60

0 · Reply

Market Cap	304.41M
Revenue (ttm)	0.00
Net Income (ttm)	-71.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	235,900
Avg Vol	387,842
Day's Range	N/A - N/A
Shares Out	35.86M
Stochastic %K	70%
Beta	1.74
Analysts	Sell
Price Target	$9.67